(Total Views: 787)
Posted On: 06/27/2022 9:22:04 PM
Post# of 148899
crazyjogger925 said Pitt from YMB seems to have some nice info. He posted this today in response to a poster who asked him why he no longer thinks CYDY is actively recruiting a CEO:
yes I did (think a new CEO would be announced) based on info from another high up biotech executive that told me he heard in their level that CYDY made an offer to a CEO. But now and since then I think differently. The due diligence supports a very strong possibility 70 % in my estimate that we are in a buyout mode. There are way too many blunt and subtle hints.
1. First we do have an amazing Multi platform monoclonal antibody that has a very unique MOA!
Proven efficacy in ph1 to ph3 trials in Major Medical needs indications: HIV, NASH, Covid, mTNB, Long Haulers and now a hidden gem we will hear about on the CC.Alzheimers and it's progress in trial.
2. No CEO
3. No concern on Share Price.
4. No PRs holding everything close to vest.
5. Attending major medical conferences like ASOC and EASL to promote justification for a Big Pharmas acquisition!
6. My thought is GSK because they have invested in Dostarlimab and it's a monoclonal antibody but it may only help people that's genes can't repair DNA. So it combined with Leronlimab would be powerful. Plus stands to reason that GSK has drug deeper into this monoclonal antibody Dostarlimab to have a better understanding what LL brings to the table.
7. GSK is spinning off their health care staples from just the biotech side on 18 July. The new company/name Haleon.
Haleon (pronounced "Hay-Lee-On"
is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'.
7. GSK built the latest and greatest cold production and automated HIV and infectious Disease medicine manufacturing plant in the world. They named it Q block. For those that don't know Q is a letter code of solidarity between white hats in the medical community. Drs and Nurses and others. It's a pledge to erradicate all diseases in the world that could be through break through medicines being controlled or shelved due to big pharma. The white hats are very aware of Leronlimab and want it in use. So GSK rebranding and new commitment to treat over 10 billion people in 10 years with currently incurable diseases. Named their new manufacturing plant "Q Block".
8. Big Pharmas don't partner with small companies as a rule. They typically buyout companies in the under 15 billion range. It's not worth their time and money and liability to partner.
9. CYDY has had NDAs for a long time now!
10. All the new doctors and executive positions being realigned and retitled. Why, To match the big pharma organization chart. I believe all on board at the buyout will get acquired to help and ensure Leronlimab jells with GSK.
Just my thoughts.
He wrote this in response to a question about his thoughts on a buy-out price:
so I know longs say they won't vote for a low ball buyout. BUT if Tanya and Scott tell us we either do this or CYDY goes bankrupt and Leronlimab is acquired by the company holding it for the 6 million dollar collateral to secure our Amerex case bond money. So honestly to be bought out without any approvals but a lot of great info of late I'm looking at Lowest price 5 billion 6 bucks a share to the actual sweet spot between 8 to 12 billion or 10 to 15 a share. If we have a behind door agreement coordinated between CYDY, GSK and the FDA on the HIV BLA and FDA is ready to view the final piece of the BLA and approve it. Remember it's a rolling BLA. Then we can easily expect 20 billion plus or 23 to 25 a share for just HIV approved and the others in the works.
yes I did (think a new CEO would be announced) based on info from another high up biotech executive that told me he heard in their level that CYDY made an offer to a CEO. But now and since then I think differently. The due diligence supports a very strong possibility 70 % in my estimate that we are in a buyout mode. There are way too many blunt and subtle hints.
1. First we do have an amazing Multi platform monoclonal antibody that has a very unique MOA!
Proven efficacy in ph1 to ph3 trials in Major Medical needs indications: HIV, NASH, Covid, mTNB, Long Haulers and now a hidden gem we will hear about on the CC.Alzheimers and it's progress in trial.
2. No CEO
3. No concern on Share Price.
4. No PRs holding everything close to vest.
5. Attending major medical conferences like ASOC and EASL to promote justification for a Big Pharmas acquisition!
6. My thought is GSK because they have invested in Dostarlimab and it's a monoclonal antibody but it may only help people that's genes can't repair DNA. So it combined with Leronlimab would be powerful. Plus stands to reason that GSK has drug deeper into this monoclonal antibody Dostarlimab to have a better understanding what LL brings to the table.
7. GSK is spinning off their health care staples from just the biotech side on 18 July. The new company/name Haleon.
Haleon (pronounced "Hay-Lee-On"
is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'. 7. GSK built the latest and greatest cold production and automated HIV and infectious Disease medicine manufacturing plant in the world. They named it Q block. For those that don't know Q is a letter code of solidarity between white hats in the medical community. Drs and Nurses and others. It's a pledge to erradicate all diseases in the world that could be through break through medicines being controlled or shelved due to big pharma. The white hats are very aware of Leronlimab and want it in use. So GSK rebranding and new commitment to treat over 10 billion people in 10 years with currently incurable diseases. Named their new manufacturing plant "Q Block".
8. Big Pharmas don't partner with small companies as a rule. They typically buyout companies in the under 15 billion range. It's not worth their time and money and liability to partner.
9. CYDY has had NDAs for a long time now!
10. All the new doctors and executive positions being realigned and retitled. Why, To match the big pharma organization chart. I believe all on board at the buyout will get acquired to help and ensure Leronlimab jells with GSK.
Just my thoughts.
He wrote this in response to a question about his thoughts on a buy-out price:
so I know longs say they won't vote for a low ball buyout. BUT if Tanya and Scott tell us we either do this or CYDY goes bankrupt and Leronlimab is acquired by the company holding it for the 6 million dollar collateral to secure our Amerex case bond money. So honestly to be bought out without any approvals but a lot of great info of late I'm looking at Lowest price 5 billion 6 bucks a share to the actual sweet spot between 8 to 12 billion or 10 to 15 a share. If we have a behind door agreement coordinated between CYDY, GSK and the FDA on the HIV BLA and FDA is ready to view the final piece of the BLA and approve it. Remember it's a rolling BLA. Then we can easily expect 20 billion plus or 23 to 25 a share for just HIV approved and the others in the works.
(13)
(0)Scroll down for more posts ▼
